| . "Time-dependent classification accuracy curve under marker-dependent sampling.." Biom J. 2016;58(4):974-92. Pub Med |
| . "Receiver operating characteristic curves and confidence bands for support vector machines.." Biometrics. 2021;77(4):1422-1430. Pub Med |
| . "A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard.." Biometrics. 2015;71(2):538-47. Pub Med |
| . "ROC curve estimation under test-result-dependent sampling.." Biostatistics. 2013;14(1):160-72. Pub Med |
| . "Multicategory reclassification statistics for assessing improvements in diagnostic accuracy.." Biostatistics. 2013;14(2):382-94. Pub Med |
| . "Clinical prognostic model for older patients with advanced non-small cell lung cancer.." J Geriatr Oncol. 2019;10(4):555-559. Pub Med |
| . "Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.." Lung Cancer. 2020;141():14-20. Pub Med |
| . "Bivariate random effects meta-analysis of diagnostic studies using generalized linear mixed models.." Med Decis Making. 2010;30(4):499-508. Pub Med |
| . "Estimating personalized diagnostic rules depending on individualized characteristics.." Stat Med. 2017;36(7):1099-1117. Pub Med |
| . "Predictive accuracy of markers or risk scores for interval censored survival data.." Stat Med. 2020;39(18):2437-2446. Pub Med |
| . "Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial.." Stat Methods Med Res. 2016;25(4):1596-619. Pub Med |
| . "Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk.." Stat Methods Med Res. 2012;21(6):621-33. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(4):744-55. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(1):201-12. Pub Med |
| . "Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion.." J Vet Intern Med. 2019;33(2):726-734. Pub Med |
| . "Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation.." Biometrics. 2014;70(3):765-73. Pub Med |
| . "Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation.." Biometrics. 2014;70(3):765-73. Pub Med |
| . "Empirical pathway analysis, without permutation.." Biostatistics. 2013;14(3):573-85. Pub Med |
| . "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.." Ann Oncol. 2019;30(4):542-550. Pub Med |
| . "Stratified Fisher's exact test and its sample size calculation.." Biom J. 2014;56(1):129-40. Pub Med |
| . "Spatial regression with covariate measurement error: A semiparametric approach.." Biometrics. 2016;72(3):678-86. Pub Med |
| . "Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.." Biometrics. 2014;70(4):1003-13. Pub Med |
| . "Bayesian design of biosimilars clinical programs involving multiple therapeutic indications.." Biometrics. 2020;76(2):630-642. Pub Med |
| . "Sequential multiple assignment randomization trials with enrichment design.." Biometrics. 2017;73(2):378-390. Pub Med |
| . "Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.." Biometrics. 2012;68(2):578-86. Pub Med |
| . "Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling.." Biometrics. 2013;69(4):830-9. Pub Med |
| . "Bayesian design of noninferiority trials for medical devices using historical data.." Biometrics. 2011;67(3):1163-70. Pub Med |
| . "Hypothesis testing at the extremes: fast and robust association for high-throughput data.." Biostatistics. 2015;16(3):611-25. Pub Med |
| . "Bayesian clinical trial design using historical data that inform the treatment effect.." Biostatistics. 2019;20(3):400-415. Pub Med |
| . "Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.." Contemp Clin Trials. 2015;42():9-17. Pub Med |
| . "Meta-analysis of sequencing studies with heterogeneous genetic associations.." Genet Epidemiol. 2014;38(5):389-401. Pub Med |
| . "Power and sample size calculations for SNP association studies with censored time-to-event outcomes.." Genet Epidemiol. 2012;36(6):538-48. Pub Med |
| . "Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.." Genet Epidemiol. 2013;37(3):276-82. Pub Med |
| . "Reexamining dis/similarity-based tests for rare-variant association with case-control samples.." Genetics. 2018;209(1):105-113. Pub Med |
| . "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.." J Biopharm Stat. 2017;27(6):933-944. Pub Med |
| . "Randomized phase II clinical trials.." J Biopharm Stat. 2014;24(4):802-16. Pub Med |
| . "Seamless phase IIa/IIb and enhanced dose-finding adaptive design.." J Biopharm Stat. 2016;26(5):912-23. Pub Med |
| . "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.." J Biopharm Stat. 2015;25(1):66-88. Pub Med |
| . "Optimal two-stage log-rank test for randomized phase II clinical trials.." J Biopharm Stat. 2017;27(4):639-658. Pub Med |
| . "Phase II cancer clinical trials with heterogeneous patient populations.." J Biopharm Stat. 2012;22(2):312-28. Pub Med |
| . "Power and sample size calculation for microarray studies.." J Biopharm Stat. 2012;22(1):30-42. Pub Med |
| . "On sample size calculation for comparing survival curves under general hypothesis testing.." J Biopharm Stat. 2012;22(3):485-95. Pub Med |
| . "On enrichment strategies for biomarker stratified clinical trials.." J Biopharm Stat. 2018;28(2):292-308. Pub Med |
| . "Phase II cancer clinical trials for biomarker-guided treatments.." J Biopharm Stat. 2018;28(2):256-263. Pub Med |
| . "Sample size determination in shared frailty models for multivariate time-to-event data.." J Biopharm Stat. 2014;24(4):908-23. Pub Med |
| . "Use of historical control data for assessing treatment effects in clinical trials.." Pharm Stat. 2014;13(1):41-54. Pub Med |
| . "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.." Stat Med. 2016;35(8):1245-56. Pub Med |
| . "A model-based conditional power assessment for decision making in randomized controlled trial studies. ." Stat Med. 2017;36(30):4765-4776. Pub Med |
| . "Subgroup detection and sample size calculation with proportional hazards regression for survival data.." Stat Med. 2017;36(29):4646-4659. Pub Med |
| . "Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm.." Stat Med. 2013;32(12):2140-54. Pub Med |
